Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials

Frank Vinluan / medcitynews - Avalayn Pharma found strong investor interest in its inhalable drugs in development for two types of pulmonary fibrosis, enabling the company to upsize its IPO. Data from two mid-stage studies are expected in 2027. The post Avalyn Pharma Takes a Breath to…

AI Summary: Avalyn Pharma has substantially increased its IPO, targeting roughly $300 million to bankroll late-stage trials of its respiratory drug candidate. The move reflects strong investor enthusiasm for lung‑disease therapeutics and gives the company a bigger war chest to advance programs previously dependent on venture capital and partnerships.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Oricell raises tens of millions to expand CAR‑T efforts / 7 wks

BioMarin Phase 3 failure dims hopes for rare‑disease therapy / 8 days

Insmed shelves Brinsupri in skin indication after mid‑stage flop / 7 wks

Chiesi acquires KalVista for $1.9B to bolster rare disease pipeline / 29 days

Mid‑stage Parkinson trial failure halts drug development plans / 8 days

Gene therapy pioneers win Breakthrough Prize for CRISPR sickle‑cell work / 6 wks

FDA again rejects Aldeyra’s dry‑eye drug for weak evidence / 2 months